A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder

The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).

本研究旨在评估左旋米那普仑缓释剂（Levomilnacipran ER）相较于安慰剂，在预防重性抑郁障碍（MDD）患者抑郁症复发方面的安全性与有效性。